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Delayed graft function (DGF) following renal transplantation is a manifestation of acute
kidney injury (AKI) leading to poor long-term outcome. Current treatments have limited
effectiveness in preventing DGF. Interleukin-18 (IL18), a biomarker of AKI, induces inter-
feron-γ expression and immune activation. GSK1070806, an anti-IL18 monoclonal anti-
body, neutralizes activated (mature) IL18 released from damaged cells following
inflammasome activation. This phase IIa, single-arm trial assessed the effect of a single
dose of GSK1070806 on DGF occurrence post donation after circulatory death (DCD) kid-
ney transplantation.
Methods
The 3 mg/kg intravenous dose was selected based on prior studies and physiologically
based pharmacokinetic (PBPK) modeling, indicating the high likelihood of a rapid and high
level of IL18 target engagement when administered prior to kidney allograft reperfusion. Uti-
lization of a Bayesian sequential design with a background standard-of-care DGF rate of
50% based on literature, and confirmed via extensive registry data analyses, enabled a
PLOS ONE







Citation: Wlodek E, Kirkpatrick RB, Andrews S,
Noble R, Schroyer R, Scott J, et al. (2021) A pilot
study evaluating GSK1070806 inhibition of
interleukin-18 in renal transplant delayed graft
function. PLoS ONE 16(3): e0247972. https://doi.
org/10.1371/journal.pone.0247972
Editor: Kathrin Eller, Medizinische Universitat Graz,
AUSTRIA
Received: October 14, 2019
Accepted: December 11, 2020
Published: March 8, 2021
Copyright: © 2021 Wlodek et al. This is an open
access article distributed under the terms of the
Creative Commons Attribution License, which
permits unrestricted use, distribution, and
reproduction in any medium, provided the original
author and source are credited.
Data Availability Statement: For reasons of
privacy protection for study participants, GSK
offers access to data and materials via controlled
access. Anonymized individual participant data
from this study plus the annotated case report
form, protocol, reporting and analysis plan, data
set specifications, raw dataset, analysis-ready
dataset, and clinical study report are available for
research proposals approved by an independent
review committee. Proposals should be submitted
to www.clinicalstudydatarequest.com. A data
access agreement will be required. Similarly, while
statistical efficacy assessment with a minimal sample size. The primary endpoint was DGF
frequency, defined as dialysis requirement�7 days post transplantation (except for hyper-
kalemia). Secondary endpoints included safety, pharmacokinetics and pharmacodynamic
biomarkers.
Results
GSK1070806 administration was associated with IL18-GSK1070806 complex detection
and increased total serum IL18 levels due to IL18 half-life prolongation induced by
GSK1070806 binding. Interferon-γ−induced chemokine levels declined or remained
unchanged in most patients. Although the study was concluded prior to the Bayesian-
defined stopping point, 4/7 enrolled patients (57%) had DGF, exceeding the 50% standard-
of-care rate, and an additional two patients, although not reaching the protocol-defined DGF
definition, demonstrated poor graft function. Six of seven patients experienced serious
adverse events (SAEs), including two treatment-related SAEs.
Conclusion
Overall, using a Bayesian design and extensive PBPK dose modeling with only a small sam-
ple size, it was deemed unlikely that GSK1070806 would be efficacious in preventing DGF




Acute kidney injury (AKI) complicates 8–18% of hospital admissions, and an increasing body
of evidence shows that these acute insults are associated with short- and long-term increases in
healthcare cost, morbidity and mortality [1–3]. Delayed graft function (DGF), a consequence
of AKI, is defined as the failure of a transplanted kidney to function immediately after trans-
plantation [1], and is associated with a long-term increased risk of kidney graft failure [2]. The
rate of DGF in kidney transplant recipients varies between approximately 25% and 50%
depending on the presence of risk factors, including donor age, cold ischemic time, and the
cause of donor death [3, 4]. DGF is thought to occur as a result of ischemic renal injury associ-
ated with cellular hypoxia (depletion of adenosine triphosphate, loss of membrane potentials)
and subsequent reperfusion, which initiates inflammatory cascades (formation of reactive oxy-
gen species, immune cell stimulation, cytokine release and complement activation) [5–7]. The
inflammasome can also be activated, leading to production of the inflammatory cytokine inter-
leukin-18 (IL18) that is thought to contribute to the pathogenesis of AKI [8]. IL18, acting on
its receptors, then induces synthesis of proinflammatory cytokines, including interferon-γ
(IFNγ), thereby mediating inflammatory responses [9–12].
Clinical studies have shown that increases in urinary IL18 levels within the first few hours
after cardiac surgery or kidney transplantation are associated with a higher risk of AKI devel-
opment in native [13] and transplanted [14] kidneys, respectively. Furthermore, elevated uri-
nary IL18 levels are associated with long-term allograft dysfunction and mortality [15, 16].
More causal evidence of the role of IL18 in AKI comes from experimental rodent models of
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renal ischemic injury, in which IL18 neutralization and gene deletion are protective [17–20].
IL18 induction may also play a role in acute rejection, as suggested by data showing that ele-
vated levels of the IFNγ-inducible chemokines, IFNγ-induced protein 10 kD (IP10) and mono-
kine induced by IFNγ (MIG), are predictive of acute rejection episodes [21–24]. Indeed, IL18
was constitutively expressed in renal biopsies and serum IL18 was elevated in patients
experiencing acute allograft rejection [25].
Although machine perfusion or cooling of the donor have been suggested to provided
reductions in the rate of DGF [26, 27], there are no approved medicines for DGF treatment or
prevention [28] and the rate of DGF following kidney transplant remains high at 25–50% [3,
4]. As such, development of new therapies for the prevention of DGF remains a key unmet
need. GSK1070806 is a humanized immunoglobulin (Ig) G1 antibody that binds with high
affinity (Kd 46.0 pM) to neutralize the function of mature IL18 [29]. A single infusion of
GSK1070806 was well tolerated up to the highest doses tested (10 mg/kg in healthy individuals
and 3 mg/kg in obese individuals), where GSK1070806 treatment inhibited ex vivo stimulation
of IFNγ production and natural killer surface marker expression in whole blood assays [29].
GSK1070806 was also well tolerated in a phase II study in patients with type 2 diabetes, in
which two doses of GSK1070806 were administered 28 days apart [30].
Here we used a Bayesian sequential statistical methodology, in conjunction with a compre-
hensive contemporary renal transplantation dataset from the UK Transplant Registry, to
design a small, single-arm study evaluating the potential for the anti-IL18 monoclonal anti-
body GSK1070806 to reduce DGF in donation after circulatory death (DCD) transplanted kid-
neys. Additionally, using a three-pillar approach [31], we have applied detailed
physiologically-based pharmacokinetic (PBPK) modeling with associated sensitivity analyses
to predict GSK1070806 plasma and tissue exposure, and the extent of target engagement at the
sites of action considered relevant for the contribution of IL18 to DGF.
Materials and methods
Study design
This was a phase IIa, multicenter, single-arm Bayesian sequential design, pilot study to evaluate
the efficacy, safety, tolerability, and PK of GSK1070806 in patients undergoing renal transplan-
tation (GSK study 204824; ClinicalTrials.gov Identifier NCT02723786 https://clinicaltrials.
gov/ct2/show/NCT02723786). The trial was conducted between August 2016 and March 2018.
The trial included a screening period (at patient presentation to hospital), an inpatient
period (including pre-operative, intra-operative, and in-hospital recovery periods) and a fol-
low-up period commencing 30 days post transplantation with visits on Day 30, Day 90, Month
6, and Month 12 (Fig 1A). Transplantation took place on Day 0. Withdrawal and stopping cri-
teria are described in S1 Supplementary Material in S1 File.
A total of 9 centers in 2 countries (hospitals in the UK and Spain) were initiated to enroll
participants. Patients were identified/recruited by investigators and data collected at the study
sites. The study protocol, amendments, and informed consent form were approved by relevant
ethics committees or institutional review boards (the Scotland A Research Ethics Committee;
the NHS; Bellvitge University Hospital Clinical Research Ethics Committee). This study was
conducted in accordance with International Conference on Harmonisation of Technical
Requirements for Registration of Pharmaceuticals for Human Use, Good Clinical Practice,
and the ethical principles outlined in the Declaration of Helsinki 2008. Written informed con-
sent was obtained for each participant prior to the performance of any study-specific proce-
dures. None of the organ donors were from a vulnerable population and all donors or next of
kin provided written informed consent that was freely given.
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Study endpoints
The primary endpoint was incidence of DGF, defined by a requirement for dialysis within the
first 7 days post transplantation (except for hyperkalemia during the first 24 hours). Secondary
endpoints included assessments of graft function/survival (as measured by serum creatinine,
Screening Inpatient








GSK1070806 3 mg/kg IV (N=7)
Completed (n=6)
Withdrawn





• Did not meet inclusion criteria (n=1)
• Donor kidney had a tumor and was 
not suitable for transplant (n=1)
• Study suspended (n=1)
A
B
Fig 1. (A) Study design and (B) CONSORT flow diagram. d, day; aIL18, anti-interleukin-18; m, month; mAb, monoclonal antibody.
https://doi.org/10.1371/journal.pone.0247972.g001
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urine output, dialysis events), acute rejection (biopsy-proven, rejection biomarkers), safety
and tolerability of GSK1070806 in renal transplantation, and GSK1070806 PK/pharmacody-
namics (PD).
Study population
Study participants were adult (�18 years of age), dialysis-dependent recipients of first- or sec-
ond-time single kidney DCD transplants, with immunosuppressive standard-of-care com-
prised of either: basiliximab and mycophenolate mofetil; or azathioprine, tacrolimus, and
corticosteroids.
Patients were excluded from the study for influenza-like illness; if hospitalized or treated in
the past 30 days with parenteral antibiotics; diagnosis of hepatitis B virus infection, hepatitis C
virus infection, human immunodeficiency virus infection, or tuberculosis; or if they had
received live vaccinations or biological immunosuppression within 30 days prior to dosing.
Anti-infective prophylaxis therapy and viral testing were implemented to mitigate the theoreti-
cal elevated infection risk due to administration of the additional anti-IL18 immunosuppres-
sive GSK1070806 (S2 Supplementary Material in S1 File). Recipients with previous organ
transplantation (except first kidney or corneal transplants), malignancy in the past 5 years,
immunodeficiency, liver function tests where alanine aminotransferase >2x the upper limit of
normal and bilirubin >1.5x the upper limit of normal, or an electrocardiogram with
QTc> 480 msec were excluded. Patients were excluded, at the discretion of the investigator, if
patients had concurrent conditions deemed to pose an unacceptable risk. Full exclusion crite-
ria are listed in S3 Supplementary Material in S1 File.
Donor allograft exclusions included cold ischemic time >36 hours; age<5 years old; serol-
ogy positive for hepatitis B, hepatitis C, or human immunodeficiency virus; ABO blood type
incompatibility; and T- and/or B-cell positive crossmatch against the recipient. Full exclusion
criteria are listed in S3 Supplementary Material in S1 File.
Dosing
Study participants received a single intravenous (IV) injection of GSK1070806 (3 mg/kg; 100
mg/mL IV solution) administered prior to kidney allograft reperfusion by authorized staff at
each study site (Fig 1). This dose was selected based on PBPK modeling and prior clinical PK
data (S4 Supplementary Material, S1–S3 Figs and S1–S3 Tables in S1 File) and was antici-
pated to inhibit IL18 (>90% target engagement) rapidly (1–2 hours post dose) in both the
interstitial space of the kidney and the circulating plasma. Furthermore, the use of the 3 mg/kg
dose was well supported by the observed safety data generated in prior clinical studies where
36 patients had received�3 mg/kg [29, 30]. GSK1070806 is not currently commercially avail-
able and remains under investigational development. However, data access requests and
research proposals for GSK1070806 from independent investigators can be submitted to www.
clinicalstudydatarequest.com and http://iss.gsk.com.
Statistical analyses and sample size
The DGF rate in DCD transplanted kidneys was established previously at approximately 50%
[3] and this was confirmed with contemporary registry data held by the UK National Health
Service Blood and Transplant. Further details are provided in S5 Supplementary Material in
S1 File.
A Bayesian sequential analysis of efficacy data was planned to allow for the possibility of
stopping early for success or failure in this single-arm study. The statistical impact of various
sample sizes on type I error rates was explored for a background DGF rate of 50%, along with
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the power for detecting a targeted 35% DGF rate with the GSK1070806 experimental therapy.
This represents a 30% relative reduction in DGF from the 50% background rate (S5 Table in
S1 File), is deemed to be clinically meaningful and predictive of a significant impact on clinical
outcomes in any subsequent larger, late-stage clinical trials. Given the desire to minimize the
number of patients in this proof-of-concept study, it was planned with a maximum number of
30 patients, which was considered a feasible sample size that could be recruited at a small num-
ber of clinical sites over a reasonable time period.
Although a maximum cohort size of 30 was selected for this study, the actual number was
determined based on patients’ sequential DGF outcomes. The sample size and decision criteria
were selected to be adequately powered to detect the prespecified treatment effect and so there
was a reasonable type 1 error rate in the event treatment was ineffective. The design yielded
the probability of an erroneous “Go” decision of 0.139 when the GSK1070806 DGF rate is 50%
(i.e., null hypothesis), and a probability of an appropriate “Go” decision of 0.659 if a DGF rate
of 35% occurs (Fig 2A; S5 Table in S1 File).
“Success” at full enrolment was defined as 11 or fewer DGF events in 30 patients (<37%







































































Fig 2. Sequential decision rules. (A) Probability of a Go decision by DGF rate� (B) Sequential Go/No Go/Continue rule†. �At a maximum of 30 patients,
this design yields the probability of a Go decision of 0.139 when the GSK1070806 DGF rate is 50% (i.e., null hypothesis) and 0.69 at what has been a
clinically impactful GSK1070806 DGF rate of 35%. †The number in the first column indicates the number of patients who have completed study treatment.
A sequential Go/No Go/Continue rule is based on the predictive probability of success. A high predictive probability (PP) of success means that
GSK1070806 is likely to be efficacious by the end of the study given the observed data, whereas a low PP suggests that the treatment may not have sufficient
activity. If the PP value<2% (red region) the alternative hypothesis is rejected. If the PP is>92% (green), the conclusion may be made that GSK1070806
has better efficacy than the standard of care. If the PP is 2–92% (white region), the trial will continue to the next interim or until reaching 30 completed
patients. The sequential path observed in the study is represented by the orange line. Although the pathway ends in the white region, the decision to
terminate the study was made as only 1 of the 7 patients completing study treatment was not on dialysis and had creatine<400 μmol/L; this suggested that
it was unlikely that GSK1070806 3 mg/kg reduced the risk of DGF. DGF, delayed graft function.
https://doi.org/10.1371/journal.pone.0247972.g002
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GSK1070806 administration. With patient DGF status evaluated sequentially as each patient
reached 7 days post transplantation, early success on the primary endpoint would be declared
if the predictive probability of success was >0.92 (i.e., 92% probability the eventual number of
DGF events would be 11 or fewer if the study continued to full enrolment) and a failure would
be declared on the primary endpoint if the predictive probability of success was <0.02. Fig 2B
illustrates which events may trigger an early Go (success) decision as the predictive probability
of success is>0.92 (green box), and a No Go (failure) decision as the predictive probability of
success is<0.02 (red box).
A summary of statistical analyses for the study endpoints can be found in S6 Supplemen-
tary Material in S1 File.
Pharmacokinetic sampling
Blood samples were collected at 4–8 hours post reperfusion, Day 1, Day 2, Day 7 (or earlier at
discharge), Day 30, Day 90, Month 6, and Month 12. GSK1070806 levels were measured with
an immunoassay as previously described [29]. To calculate the area under the curve, the linear
trapezoidal method was employed for all incremental trapezoids arising from increasing con-
centrations and the logarithmic trapezoidal method was used for decreasing concentrations
(i.e., Linear Up/Log Down calculation method in Phoenix WinNonlin Professional [Certara,
NJ, USA]).
Pharmacodynamics and biomarkers
Serum. Blood samples were collected at baseline (pre-operative), 45 minutes, and 4–8
hours post reperfusion, and following transplantation on Day 1, Day 2, discharge, Day 30, Day
90, Month 6, and Month 12. Levels of free IL18 (unbound), IL18-GSK1070806 complexes, and
total IL18 (includes free IL18, IL18 bound to GSK1070806, and/or IL18 binding protein
[IL18-BP]) were measured in serum as previously described [29]. Antibody 16D10, used as the
capture antibody in total and IL18/GSK1070806 complex assays, is specific for the mature
form of IL18 and does not compete for IL18-BP. Antibody 13G9, used as the detection anti-
body in the free IL18 assay, is specific for both pro and mature forms of IL18, and competes
for IL18-BP. Additionally, the free IL18 assay used GSK1070806 as the capture antibody, so
the free IL18 assay was also specific for mature IL18. R&D systems Quantizing1 Elisa Human
IL18 BPa Kit was used for detection of serum IL18-BP. Recombinant human IL18 BPa refer-
ence standard was reconstituted and assays were conducted according to manufacturer
specifications.
Levels of serum IP10 and MIG were measured using individual Meso-Scale Discovery
immunoassays, Human IP10 V-plex plus (K151NVG) and Custom MIG K151A0H-2.
Urine. Urine samples were collected at baseline (pre-operative), 4–8 hours post reperfu-
sion, and daily following transplantation until discharge, at discharge, Day 30, Day 90, Month
6, and Month 12. Aliquots of urine were collected in sterile, screw-capped polypropylene
tubes, frozen immediately and stored at −20˚C. Total urine IL18 was assessed as described for
serum IL18. Kidney Injury Molecule-1 (KIM1) and neutrophil gelatinase-associated lipocalin
(NGAL) levels were assessed using assays performed by Biomarker services, Q2 Solutions1.
Renal biopsies. Graft biopsies (core or wedge samples) were collected approximately 45
minutes post reperfusion and fixed in 10% neutral buffered formalin, then processed to paraf-
fin block. Paraffin sections were cut at 4 microns, then stained using immunohistochemistry
(IHC) Ventana Ultra Protocol 1249. GSK1070806 was detected using a mouse anti-
GSK1070806 idiotype antibody 1H03. Total IL18 (pro and mature) was detected using a rabbit
anti-IL18 antibody (Origene TA590088). An automated protocol was optimized using the
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Ventana Discovery Ultra staining system. Anti-idiotype antibody staining in a non-dosed,




A PBPK modeling approach was used to estimate an appropriate IV dose of GSK1070806 [32,
33] in renal transplant recipients. Briefly, this technique uses physiological volumes (vascular,
extracellular, and endosomal) and fluid flows (lymph/plasma) combined with mechanistic cal-
culations of extravasation, binding, and neonatal Fc Receptor recycling to predict drug distri-
bution and elimination. As part of the validation, verification was conducted in which, model-
simulated plasma PK parameters were compared with measured PK from healthy volunteers,
showing good agreement (S4 Supplementary Material, and S3 Table in S1 File).
The kidney interstitium was considered the critical site of action, as IL18 signaling on the
basolateral receptors of the renal tubular epithelial cells is thought to mediate apoptotic signal-
ing [34]. To simulate a worst-case scenario for achieving target suppression, all IL18 synthesis
was assigned to the kidney interstitium as a zero-order reaction and was carried to plasma by
lymphatics, and to a lesser extent diffusion into capillaries. The IL18 generation rate was
adjusted to produce an IL18 plasma concentration of 835 pg/mL, which is consistent with the
90th percentile of patients with DGF [35]. The degradation rate was set to achieve an IL18 half-
life of 35 hours [36]. GSK1070806 doses of 0.1–10 mg/kg were modeled (S1 Fig in S1 File)
with the goal of identifying dose levels to achieve a>90% reduction versus baseline in free
IL18 levels in the kidney interstitium within 1–2 hours of kidney reperfusion post
transplantation.
Simulations of the 3 mg/kg dose indicated a rapid and robust decrease in free IL18 levels in
the kidney interstitial space with>80% reduction by 1 hour and>90% achieved 2 hours post
dose (Fig 3A and 3B). Maximum knockdown in free IL18 levels in the kidney of 96% was
expected approximately 43 hours post dose, inhibition >90% was maintained for 7 days
(period of assessing the DGF primary endpoint), and>85% target engagement was sustained
through the simulated 28-day time course (Fig 3C and 3D). Use of the single 3 mg/kg dose
provided a>99% reduction in circulating (plasma) levels of free IL18 within minutes post
dose and sustained over the following 28 days (S1 Fig in S1 File). The kidney interstitium is
considered a difficult tissue to penetrate, so the extensive penetration modeled for the kidney
suggests that GSK1070806 exposure should also be sufficient in other tissues if they are rele-
vant for IL18 DGF pathophysiology.
Numerous sensitivity analyses (S2 Fig in S1 File) were performed around renal blood and
lymph flow (1–300%), IL18 half-life (1–100 hours), circulating IL18 levels (100–3000 pg/mL),
and capillary-tubule distance (up to 600 μm), all supporting that the single 3 mg/kg IV dose
was the minimum that would confidently achieve >90% IL18 inhibition in the initial hours
after transplantation, during which it was presumed that the pathological processes causing
DGF would be initiated.
Further details of the simulation methodologies, model validation, and sensitivity analysis
are included in the S4 Supplementary Material, and S1–S3 Figs and S1–S3 Tables in S1 File.
Patient and donor characteristics, and trial flow
Ten patients were screened, and seven patients were enrolled and received a single
GSK1070806 3 mg/kg IV dose. One patient was lost to follow-up prior to the 12-month study
visit (Fig 1B). Donor- and recipient-paired baseline demographic characteristics are
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summarized in Table 1; additional baseline characteristics of the recipients are shown in
Table 2. All patients were male between 33 and 72 years of age. The study was terminated pri-
marily due to an overall lack of efficacy after the seventh patient was assessed for DGF. Recruit-
ment was also slower than expected.
Efficacy
Of the seven patients enrolled, four exhibited DGF (Table 1). This outcome (57% DGF rate,
95% credible interval [CrI]: 25–90%) exceeded the 50% expected standard-of-care rate. The
sequential path in Table 1, represented by the orange line in the grid in Fig 2B, was as follows
(note that patients were not evaluated in the same order as they were enrolled): no DGF
(Patient 1), DGF (Patient 2), no DGF (Patient 3), DGF (Patient 5), no DGF (Patient 6), DGF
(Patient 4), and DGF (Patient 7), with Patient 6 receiving dialysis for hyperkalemia. Only one


















































































































Fig 3. Simulation of drug exposure in the kidney interstitium based on IL18 suppression using PBPK modeling up to 6 hours (A) and 90 days (B) post dose.
Predicted drug concentration and free/bound IL18 in the kidney interstitium up to 4 hours (C) and 1-month (D) post dose with 3 mg/kg. IL18, interleukin-18,
PBPK, physiologically-based pharmacokinetic modeling.
https://doi.org/10.1371/journal.pone.0247972.g003
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of the seven patients (Patient 1) had creatinine levels <400 μmol/L and did not require dialysis
over the first 4 days. The posterior probability that <30% of patients would experience DGF
was 7% (95% CrI: 0–100%), and the posterior probability that <50% of patients would experi-
ence DGF was 34% (95% CrI: 0–100%).
Serum creatinine was elevated at baseline in all patients, ranging between 448 μmol/L and
996 μmol/L, and generally remained elevated over 6 days post transplantation (Fig 4A). Over-
all, serum creatinine had decreased at 12 months in all patients, irrespective of the presence of
DGF (Fig 4B and S4 Fig in S1 File). A protracted recovery of urine output was observed in
most cases (Fig 4A).
Safety and tolerability
Six (86%) patients experienced a total of 17 serious adverse events (SAEs) (S6 Table in S1
File). The seventh patient enrolled developed an SAE of ventricular fibrillation and cardiac
arrest (non-fatal) intra-operatively. This event was considered unrelated to GSK1070806, as
the patient had multiple risk factors for coronary artery disease and had been experiencing
chest pain prior to transplantation. Subsequently, this patient also developed an SAE of visceral
leishmaniasis not considered related to study treatment. Another patient experienced two
SAEs, pneumonia and respiratory arrest, considered related to study treatment. In a further
patient, an SAE of acute cellular rejection was observed at Day 57 and was considered unre-
lated to treatment, with a biopsy at Day 59 showing a borderline rejection result. All SAEs
were resolved and no fatal SAEs occurred.
All patients experienced�1 AE, most frequently anemia (5/7; 71%), constipation (4/7;
57%), diarrhea (3/7; 43%), and urinary tract infection (3/7; 43%). No AEs led to study with-
drawal. Five patients experienced AEs considered related to GSK1070806 (Table 3), most
commonly anemia (4/7; 57%), as well as several infections, including urinary tract infections,
bacterial disease carrier, nail infection, pharyngotonsillitis, postoperative wound infection,
purulent discharge, acute pyelonephritis, influenza, and lower respiratory tract infection. With
the exception of the SAE of cardiac arrest, there were no clinically significant electrocardiogra-
phy abnormalities during the study. While other clinically significant laboratory abnormalities
were recorded during the study, they were as expected for this patient population.
Table 1. Donor and recipient paired baseline demographic characteristics and DGF outcomes.
Donor Recipient
Age (years) Sex WIT (min) CIT (min) Patient # Age (years) Sex Weight (kg) Sequence� DGF
61 M 9† 811 1 71 M 80 1 N
57 F 22 978 2 63 M 107 2 Y
65 M 9 678 3 56 M 111 3 N
36 F 19 793 4 33 M 87 6 Y
59 M 15 514 5 64 M 98 4 Y
52 M 15 540 6 72 M 64 5 N
61 M ND 1246 7 52 M 104 7 Y
All donor and recipients were of European ethnicity. None of the donor kidneys were transported using a cold machine perfusion system, except that received by
Patient 54. Only DCD kidneys were used.
�Sequence indicates the order of evaluation for Bayesian sequential study design (Fig 2B).
†Donor WIT for Patient 1 was originally erroneously reported as 4 minutes as it did not include the 5-minute mandatory waiting period between circulatory arrest and
initiation of surgery, per UK legislation.
DCD, donation after circulatory death; DGF, delayed graft function; CIT, cold ischemic time; N, no; ND, no data; WIT, warm ischemic time; Y, yes.
https://doi.org/10.1371/journal.pone.0247972.t001
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Pharmacokinetics
Plasma PK results for GSK1070806 are summarized in S7 Table in S1 File. A mean (95% confi-
dence interval [CI]) maximum observed concentration of 53.14 (29.69–76.59) μg/mL was
achieved. Mean (95% CI) serum half-life was 37.96 (32.77–43.15) days and mean (95% CI) area
under the concentration-time curve from time zero to infinity was 43.27 (27.34–59.19) h�mg/mL.
Table 2. Baseline demographics and clinical characteristics of patients receiving GSK1070806.
GSK1070806 3 mg/kg IV (N = 7)





Hispanic or Latino 0 (0)
Non-Hispanic or Latino 7 (100)
Height (cm), mean (SD) 179.1 (9.35)
Weight (kg), mean (SD) 92.97 (16.806)
BMI (kg/m2), mean (SD) 29.20 (6.014)
Current medical conditions�
Cardiovascular risk factors, n (%)
Any condition 7 (100)
Hypertension 7 (100)
Hyperlipidemia 2 (29)
Angina pectoris 1 (14)
Diabetes 1 (14)
Renal and urinary disorders, n (%)
Any condition 5 (71)
Glomerulonephritis/autoimmune 2 (29)
Hypertensive nephropathy 1 (14)
Polycystic kidney disease 1 (14)
Sequelae of systemic autoimmunity 1 (14)
Other condition, n (%)
Any condition 6 (86)
Respiratory, thoracic, and mediastinal disorders 2 (29)
Gout 2 (29)
Anemia normocytic 1 (14)
Endocrine disorders 1 (14)
Hepatobiliary disorders 1 (14)
Immune system disorders 1 (14)
Known left ventricular hypertrophy 1 (14)
Musculoskeletal and connective tissue disorders 1 (14)
Psychiatric disorders 1 (14)
Pacemaker inserted 1 (14)
Scleritis 1 (14)
Vascular disorders 1 (14)
Anemia 1 (14)
�Current medical conditions were collected as per the protocol but summarized post-hoc; patients may have had
more than one current medical condition.
https://doi.org/10.1371/journal.pone.0247972.t002
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Pharmacodynamics and biomarkers
Serum IL18 levels (total and IL18-GSK1070806 complex) rose rapidly following dosing and
transplantation and remained high for a prolonged period (Fig 5A and 5B). Serum IL18-BP
levels were reduced by as much as 2-fold following treatment (Fig 5C). Levels of free IL18
were predominantly at or below the lower limit of quantification at baseline and throughout
the study; as a result, sampling was discontinued part-way through the trial, therefore data are
sparse.
Fig 4. (A) Creatinine levels and urine output during the first 7 days following transplantation. (B) Mean serum creatinine by DGF occurrence over the study course.
There was some variability between patients in timeframe and extent of data collection: Patient 1, no data collected for Days 5 and 6; Patient 5, urine output was
negligible during this period; Patient 7, urine output not recorded due to patient undergoing continued dialysis during this period. Any event occurring at any time
within a calendar day was charted at that study day, e.g., for Patient 4, dialysis at Day 1 as shown on the chart may have occurred at any time point during Day 1. DGF,
delayed graft function.
https://doi.org/10.1371/journal.pone.0247972.g004
Table 3. Summary of drug-related adverse events by system organ class.
System organ class preferred term Patients, n (%) N = 7
Any event 5 (71)
Blood and lymphatic system disorders




Any event 3 (43)
Blood temperature decreased 1 (14)
Cytomegalovirus test positive 1 (14)
Hemoglobin increased 1 (14)
Infections and infestations
Any event 2 (29)
Influenza 1 (14)
Lower respiratory tract infection 1 (14)
Pneumonia 1 (14)
Injury, poisoning and procedural complications
Any event 2 (29)
Arteriovenous fistula site complication 1 (14)
Wound dehiscence 1 (14)
Skin and subcutaneous tissue disorders




Any event 1 (14)
Lip swelling 1 (14)
Metabolism and nutrition disorders
Any event 1 (14)
Hypoalbuminemia 1 (14)
Hypomagnesemia 1 (14)
Respiratory, thoracic and mediastinal disorders
Any event 1 (14)
Respiratory arrest 1 (14)
https://doi.org/10.1371/journal.pone.0247972.t003
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Urinary IL18 levels were monitored in five patients; levels were low, except in two patients
(Patients 2 and 3) who had levels above 100 pg/mL within the first 2 postoperative days, which
is considered predictive of increased AKI risk [37] (S8 Table in S1 File). After transplant, uri-
nary NGAL levels were elevated above 153 ng/mL and urinary KIM1 levels were above 2.37
ng/mL in all six patients for whom data were available (Patients 1–6); these levels of NGAL
[38] and KIM1 [37] are considered predictive of AKI progression (S8 Table in S1 File).
Serum levels of IFNγ, which is directly induced by IL18, were low (between 0.05 pg/mL and
11 pg/mL) except in Patient 7, in whom they rose to 22 pg/mL by 90 days and 124 pg/mL by 6
months. Generally, IFNγ decreased to Day 1, after which levels increased. IP10 levels were
largely unchanged over the course of treatment, except in Patient 7, in whom the levels
decreased through Day 58 and increased nearly 4-fold from pretreatment levels thereafter. In
Patient 4, after an initial decline to 8 hours post dose, IP10 levels increased and generally
remained elevated, with two transient peaks at Day 2 and Day 12; this patient experienced
transplant rejection on Day 57. Serum MIG levels generally decreased across the first 30 days,
before beginning to increase towards the end of the study period. Changes in MIG levels mir-
rored those of IFNγ and IP10 in Patient 7 (Fig 6).
Levels of additional serum cytokines IL1β, IL2, IL8, macrophage inflammatory protein 1β,
monocyte chemoattractant protein, and tumor necrosis factor-α are shown in S5 Fig in S1
File. Overall levels were consistent with low or diminishing proinflammatory responses over
the course of treatment.
Histology
Histological assessments of biopsies taken approximately 45 minutes post reperfusion showed
varying degrees of pre-existing pathology that may have contributed to the attenuated allograft
function observed in this study. Hematoxylin and eosin staining revealed moderate tubular
vacuolation and basement membrane thickening in DGF Patients 2 and 4, and extensive base-
ment membrane thickening, increased connective tissue, and dilated Bowman’s space in DGF
Patient 5 (S6 Fig in S1 File). No biopsies were available for analysis for DGF Patient 7 or no-
DGF Patient 6.
Total tissue IL18 (pro-IL18 and mature IL18) and GSK1070806 staining was assessed by
IHC in five of the seven patients (Fig 7A). GSK1070806 staining was observed within the epi-
thelium of a subset of distal tubules, was distributed heterogeneously, and coincided to a lim-
ited degree with total IL18 expression in the same regions (Fig 7B). Signal-to-noise within and
between patients was variable although background IgG1 isotype staining did not contribute
to this (Fig 7C). A non-dosed and non-transplanted control kidney was stained with
GSK1070806 as the primary antibody (to identify mature IL18 only), showing strong IL18
staining in a subset of tubular epithelial cells and moderate staining in the luminal spaces of a
subset of tubules, consistent with the pattern of anti-IL18 staining in biopsies from the study
(S7 Fig in S1 File).
Discussion
In this study, neutralization of IL18 with GSK1070806 was evaluated for the prevention of
DGF following renal transplantation using a single-arm Bayesian sequential design. Four of
seven patients (57%) satisfied the definition of DGF. Two further patients had high creatinine
Fig 5. Serum levels of (A) IL18-GSK1070806 complex, (B) total IL18, and (C) IL18-BP over the study course. BP,
binding protein; IL18, interleukin-18. Figures produced post hoc.
https://doi.org/10.1371/journal.pone.0247972.g005
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Fig 6. Serum cytokine levels over the study course. (A) IFNγ, (B) IP10, (C) MIG. IFNγ, interferon-γ; IP10, IFNγ-













Fig 7. Dual immunohistochemical detection. (A) Co-distribution of GSK1070806 (pink) with IL18 (yellow) in wedge
biopsies from Patient 2. Nuclei stained with hematoxylin. (B) 200x magnified region of Patient 2 biopsy, taken from
the area outlined in A, showing the luminal co-distribution of GSK1070806 (pink) and IL18 (yellow) in the tubules.
(C) Isotype control staining. IL18, interleukin-18.
https://doi.org/10.1371/journal.pone.0247972.g007
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levels in the postoperative period, one of whom required dialysis for hyperkalemia, leaving
only one of seven patients who was not on dialysis and with creatine <400 μmol/L. Collec-
tively, these data suggested that it was unlikely that GSK1070806 3 mg/kg reduced the risk of
DGF. Based on this evidence, the trial was terminated.
Several clinical studies have been performed to evaluate the effect of novel investigational
medicines on the incidence of DGF. These studies have been largely unsuccessful and require
the recruitment of large numbers of patients using placebo comparator designs to evaluate effi-
cacy [39]. Utilizing a Bayesian approach to minimize sample size reduces investment barriers
to evaluating new therapies (both clinical trial resource and funding), exposes fewer patients to
investigational medicines with limited safety profiles, and enables efficient decision making.
Indeed, the novel Bayesian sequential approach in this study, using the background DGF rate
determined from literature and confirmed with registry data formed the Go/No Go design,
allowed for fewer patient exposures and avoided the need for a control arm. Each patient
enrolled in this study had a varied risk for DGF at baseline based on their individual character-
istics. This was accounted for as closely as possible when confirming the background DGF rate
using registry data, in which only patients meeting the current clinical trial inclusion/exclusion
criteria and treated at recruiting sites were used to confirm the 50% DGF background rate.
From a development perspective, if this initial proof-of-concept study had indicated that there
was the potential for GSK1070806 to reduce DGF, the results would have been confirmed in a
randomized double-blind placebo-controlled study.
Consistent with the poor renal function in 6/7 patients in the study, urinary levels of NGAL
and KIM1 were elevated post-transplant in all six patients for whom data were available. Uri-
nary IL18 levels were low, except in two patients, whose elevated levels were observed immedi-
ately following or within 2 days post-transplantation. One possible explanation for the overall
lower levels of urinary IL18 could be sequestration of IL18 within the kidney or circulation via
formation of IL18-GSK1070806 complexes. Furthermore, urinary IL18 levels appear non-cor-
related with postoperative graft function, as the patient with the highest urinary IL18 level did
not experience DGF.
PD analyses showed serum levels of total IL18 and IL18-GSK1070806 complexes climbed
rapidly following transplantation and remained high for a prolonged period, reflecting periph-
eral blood IL18 target engagement with GSK1070806 enhancing IL18 half-life. This is consis-
tent with the first-in human study [29]. However, serum levels of total IL18 in this study
showed large variation between patients, especially by the end of the study. This is perhaps not
surprising, given that the first-in-human study included relatively healthy participants,
whereas the present study comprised a complex patient population. Extraneous factors may
have been involved in the observed IL18 variability, such as visceral leishmaniosis infection in
Patient 7 and pyelonephritis and rejection events in Patient 4.
Although acute allograft rejection was not assessed directly in this study (e.g., via surveil-
lance biopsies), an exploratory evaluation of the potential impact of GSK1070806 on acute allo-
graft rejection was performed by measuring serum levels of IFNγ and IFNγ-inducible
chemokines, IP10 and MIG, which are predictive of acute rejection episodes [22–24]. Levels of
MIG in most patients were unchanged over the study and levels of IFNγ and IP10 initially
declined in most patients following treatment, consistent with antagonism of IFNγ−induced
Th1 cytokine responses and predicting a low probability of acute rejection occurrence. One
case of acute rejection occurred (Patient 4; event considered unrelated to study treatment)
with elevated levels of IP10, MIG and total IL18 corresponding to the rejection event. No rejec-
tion was observed in Patient 7 despite steady increases in IP-10 and MIG throughout the
study, suggesting their elevated levels were associated with a different mechanism (e.g., long-
term sequelae of visceral leishmaniasis).
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While these data indicate engagement in the circulation, they may not reflect GSK1070806
activity in the kidney interstitium, which could be the relevant site of action. By IHC of kidney
biopsies, we were able to identify the presence of GSK1070806 outside of the renal vasculature,
indicating that GSK1070806 did penetrate the transplanted kidney tissue. GSK1070806 selec-
tively binds human mature IL18 with a high affinity (Kd = 46.0 pM at 37˚C) and neutralizes its
function [30], but GSK1070806 has a much lower affinity for pro-IL18 (Kd = 46.7 nM at 37˚C)
(S7 Supplementary Material, S4 Table in S1 File). Therefore, we would not expect
GSK1070806 to bind pro-IL18 at the anticipated GSK1070806 exposures in vivo. The IL18
antibody used for IHC labeling in renal biopsies from patients treated with GSK1070806 in
this study does not differentiate between pro and mature IL18, so the observed staining results
potentially include both forms. With just one post-dose biopsy from each patient, we are
unable to eliminate the possibility of regional differences in drug distribution. Additional con-
founding factors include the small sample size, inter- and intra-sample variation, and the type
of biopsy collected (3 wedge and 2 needle). Therefore, the IHC findings should be interpreted
with caution: solely based on the IHC data we cannot conclude whether therapeutically rele-
vant exposure was achieved within the kidney during acute reperfusion (as predicted by the
PBPK modeling); we can conclude only that GSK1070806 was present along with pro and/or
mature IL18.
Achieving exposure within the interstitium of the kidney with sufficient rapidity to inhibit
IL18 after kidney reperfusion was deemed of potentially critical importance in this study and
triggered substantial modeling efforts prior to dose selection. Extensive sensitivity analyses
completed using the PBPK modeling approach allowed us to confidently select the single
GSK1070806 3 mg/kg IV dose level evaluated here for its ability to reduce the occurrence of
DGF. Dose escalation to 10 mg/kg was considered following the lack of efficacy observed in
this study. However, the PBPK modeling results predicted substantial IL18 inhibition in the
first hours following transplantation at the 3 mg/kg dose, and it was considered unlikely that
increasing exposure with the maximum dose previously tested (10 mg/kg) would improve effi-
cacy (Fig 3). Although the renal interstitium was hypothesized as the site of action for
GSK1070806, if neutralization was only required in the circulation GSK1070806 at the 3 mg/
kg dose was predicted to achieve >99% IL18 suppression within minutes of administration.
Note, plasma PK in this study was in line with that observed in the first-in-human study fol-
lowing administration of a single 3 mg/kg dose [29], and a phase II study assessing
GSK1070806 in patients with type 2 diabetes [30]. However, we cannot preclude the possibility
that IL18 neutralization occurred too late in the pathological process of DGF. Although we
hypothesized that injury occurs upon reperfusion, it is possible that it occurs prior to trans-
plantation, which could be an explanation for the lack of efficacy observed in this study. While
it is possible that IL18 inhibition in donors prior to kidney removal or during organ transport
(e.g., through a normothermic perfusion/preservation circuit) would have been beneficial in
reducing risk of DGF, ethical and operational issues make these hypotheses difficult to evaluate
and no such studies are planned.
All patients reported AEs, and 6 of the 7 patients enrolled experienced SAEs; all SAEs were
resolved and there were no fatalities. Overall, the AEs recorded were as expected for patients
undergoing kidney transplantation; indeed, all patients had multiple comorbidities and subop-
timal kidney function. Although most patients reported SAEs consistent with an unwell trans-
plant population, only two of the SAEs, both occurring in one patient, were considered related
to GSK1070806 (pneumonia and respiratory arrest). Relatedness was indicated due to the
potential of the study drug to magnify immunosuppression. In addition to the drug-related
SAE of pneumonia, other non-serious infections considered related to GSK1070806 occurred.
One patient experienced a cardiac event, which was deemed unrelated to study treatment.
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This patient was found to have critical coronary stenoses on post-operative angiography,
which suggested a chronic cause of cardiac complications. End-stage renal disease is associated
with two-fold increase in risk of death from cardiovascular disease [40] and, in the post renal
transplant setting, cardiovascular disease is reported to be the leading cause of death with graft
function (36.1%) [40]. In previous studies, GSK1070806 was well tolerated with no reported
cardiac complications [29, 30]; however, we cannot completely rule out a possible effect of the
study drug in the observed cardiac event.
In conclusion, this study does not provide data supporting efficacy of GSK1070806 in pre-
venting DGF after DCD renal transplantation in the recruited this patient population. How-
ever, utilization of the novel Bayesian sequential study design enabled rapid decision making
to not proceed further with the development of GSK1070806 for renal transplantation, and
hence avoided excess exposure of patients to the investigational drug. Although we were not
able to measure target engagement directly in the kidney interstitium, based on PBPK model-
ing and associated sensitivity analyses, we are compelled to think that the 3 mg/kg dose pro-
vided sufficient exposure in these patients; and that our negative clinical findings are due to a
lack of efficacy in response to IL18 neutralization at the time of reperfusion, rather than poor
exposure/target engagement with GSK1070806.
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